V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310002847 | 310001215 | 1.85 | null | Palliative (P) | 2017-04-15 | 2017-04-16 | CHOP R | N | N | 310016365 | CHOP R |
| 310002848 | 310001215 | null | 58.2 | Palliative (P) | 2016-05-09 | 2016-05-09 | CHOP R - 21 days | 02 | N | 310016365 | CHOP R |
| 310002849 | 310001215 | 1.68 | 74.6 | Palliative (P) | 2017-10-10 | 2017-10-10 | Ipilimumab | N | N | 310016365 | IPILIMUMAB |
| 310002850 | 310001216 | null | 86.6 | Palliative (P) | 2013-03-20 | 2013-03-31 | Ipilimumab | 02 | N | 310016373 | IPILIMUMAB |
| 310002851 | 310001216 | 1.93 | 99.7 | Palliative (P) | 2015-02-20 | 2015-03-01 | PEMBROLIZUMAB | 02 | N | 310016373 | PEMBROLIZUMAB |
| 310002853 | 310001217 | 1.74 | 62.2 | Palliative (P) | 2013-10-27 | 2013-11-16 | DOXORUBICIN | N | null | 310016377 | DOXORUBICIN |
| 310002854 | 310001218 | 1.7 | 79.6 | Curative (C) | 2018-03-18 | 2018-03-28 | Trial Unspecified | N | N | 310016379 | TRIAL |
| 310002855 | 310006470 | null | 83 | Adjuvant (A) | 2016-12-03 | 2017-11-06 | Retinoblastoma JOE | N | N | 310016380 | CEV |
| 310002856 | 310006470 | 1.66 | 55 | Palliative (P) | 2017-06-15 | 2017-06-29 | PEMBROLIZUMAB | N | N | 310016380 | PEMBROLIZUMAB |
| 310002857 | 310001219 | 1.69 | 70 | Palliative (P) | 2015-01-01 | 2015-01-30 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 310016390 | CISPLATIN + GEMCITABINE |
| 310002858 | 310001219 | 1.66 | 10.6 | Palliative (P) | 2017-05-15 | 2017-05-16 | Carboplatin + Etoposide iv&po | 02 | N | 310016390 | CARBOPLATIN + ETOPOSIDE |
| 310002859 | 310001220 | 1.6 | null | Curative (C) | 2016-12-12 | 2017-01-10 | Cisplatin 7 day | 02 | Y | 310016397 | CISPLATIN |
| 310002860 | 310006472 | 1.9 | 86.6 | Adjuvant (A) | 2013-11-05 | 2013-11-19 | CHEMO-T TRIAL | 01 | null | 310016401 | TRIAL |
| 310002861 | 310008962 | 1.67 | null | Palliative (P) | 2016-09-09 | 2016-12-25 | Trial Unspecified | 1 | N | 310016402 | TRIAL |
| 310002862 | 310001221 | 1.8 | 117.3 | null | 2014-07-02 | 2014-07-17 | Cisplatin 7 day | N | Y | 310016410 | CISPLATIN |
| 310002863 | 310001222 | null | null | Curative (C) | 2014-11-28 | 2014-12-02 | Retinoblastoma JOE | null | N | 310016411 | CEV |
| 310002864 | 310001222 | 1.79 | 78.4 | Curative (C) | 2016-01-10 | 2016-01-23 | Cisplatin | null | N | 310016411 | CISPLATIN |
| 310002865 | 310001222 | 1.78 | 69.2 | Curative (C) | 2017-12-08 | 2017-12-15 | Trial Unspecified | 01 | N | 310016411 | TRIAL |
| 310002866 | 310001222 | 1.77 | 103.8 | Palliative (P) | 2017-01-06 | 2017-01-18 | PEMBROLIZUMAB | 2 | N | 310016411 | PEMBROLIZUMAB |
| 310002867 | 310001222 | null | 67.6 | Adjuvant (A) | 2014-07-16 | 2014-07-17 | Cisplatin 7 day | N | N | 310016411 | CISPLATIN |
| 310002868 | 310001222 | 0 | 50.9 | Curative (C) | null | 2015-06-25 | Retinoblastoma JOE | N | N | 310016411 | CEV |
| 310002869 | 310001222 | null | 86 | Palliative (P) | 2013-03-18 | 2013-04-01 | Cisplatin | N | N | 310016411 | CISPLATIN |
| 310002870 | 310001223 | 1.7 | 78.9 | Palliative (P) | 2016-10-08 | 2016-10-08 | PEMBROLIZUMAB | 02 | N | 310016449 | PEMBROLIZUMAB |
| 310002871 | 310001224 | null | 95.2 | Palliative (P) | null | 2015-01-24 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 310016452 | CISPLATIN + GEMCITABINE |
| 310002872 | 310001225 | 1.72 | 65.5 | Palliative (P) | 2015-06-19 | 2015-06-21 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 310016457 | CISPLATIN + GEMCITABINE |
| 310002873 | 310001225 | 1.92 | 64.9 | Neo-adjuvant (N) | 2015-06-20 | 2015-06-27 | CISPLATIN + GEMCITABINE | 02 | N | 310016457 | CISPLATIN + GEMCITABINE |
| 310002874 | 310001226 | 1.74 | null | Palliative (P) | 2016-11-28 | 2016-12-04 | PEMBROLIZUMAB | 02 | N | 310016465 | PEMBROLIZUMAB |
| 310002875 | 310001227 | 1.7 | 81 | null | 2017-04-12 | 2017-04-12 | Cisplatin 7 day | 02 | null | 310016469 | CISPLATIN |
| 310002876 | 310001228 | 1.83 | 63.9 | Palliative (P) | 2015-10-11 | 2015-10-25 | DOXORUBICIN | null | N | 310016471 | DOXORUBICIN |
| 310002878 | 310001230 | 1.75 | 64 | Curative (C) | 2016-01-31 | 2016-02-07 | CHOP R - 21 days | 02 | N | 310016473 | CHOP R |
| 310002879 | 310001231 | 1.74 | 99.8 | Palliative (P) | 2017-02-15 | 2017-03-07 | Ipilimumab | N | N | 310016477 | IPILIMUMAB |
| 310002880 | 310001232 | 1.74 | 81.3 | null | 2018-02-27 | 2018-03-06 | PEMBROLIZUMAB | 02 | N | 310016481 | PEMBROLIZUMAB |
| 310002881 | 310001233 | 1.7 | 68 | Palliative (P) | 2017-08-18 | 2017-08-20 | PEMBROLIZUMAB | 02 | N | 310016484 | PEMBROLIZUMAB |
| 310002882 | 310006475 | 1.73 | 72.65 | Palliative (P) | 2016-12-26 | 2016-12-26 | Trial Unspecified | 01 | null | 310016491 | TRIAL |
| 310002883 | 310006475 | 1.78 | 97 | Curative (C) | 2014-01-10 | 2014-01-19 | CHOP R | N | N | 310016491 | CHOP R |
| 310002884 | 310006475 | 1.75 | 67 | Palliative (P) | 2016-03-10 | 2016-03-24 | Doxorubicin 75mg/m2 | N | N | 310016491 | DOXORUBICIN |
| 310002885 | 310006475 | 1.89 | 81.3 | Adjuvant (A) | null | 2017-05-07 | Cisplatin | null | Y | 310016491 | CISPLATIN |
| 310002886 | 310001234 | 1.57 | 68 | Palliative (P) | 2015-03-02 | 2015-03-02 | DOXORUBICIN | 02 | N | 310016506 | DOXORUBICIN |
| 310002887 | 310001235 | 1.6 | 68 | Neo-adjuvant (N) | 2013-08-11 | 2013-08-25 | CISPLATIN + GEMCITABINE | N | N | 310016507 | CISPLATIN + GEMCITABINE |
| 310002888 | 310001236 | 1.57 | 8.6 | Not known (9) | 2018-11-06 | 2018-11-06 | Ipilimumab | 2 | N | 310016512 | IPILIMUMAB |
| 310002889 | 310001236 | 0 | 67.6 | Curative (C) | 2015-10-07 | 2015-10-14 | Retinoblastoma JOE | N | N | 310016512 | CEV |
| 310002890 | 310001236 | 1.68 | 80.7 | Adjuvant (A) | 2013-08-30 | 2013-09-12 | CISPLATIN + GEMCITABINE | N | N | 310016512 | CISPLATIN + GEMCITABINE |
| 310002891 | 310010281 | null | 49.8 | Curative (C) | 2013-11-27 | 2013-11-29 | Cisplatin 7 day | 02 | N | 310016521 | CISPLATIN |
| 310002892 | 310001237 | 1.65 | null | Palliative (P) | 2019-05-19 | 2019-05-20 | Doxorubicin 75mg/m2 | 02 | null | 310016525 | DOXORUBICIN |
| 310002893 | 310001238 | 1.6 | null | Palliative (P) | 2017-02-04 | 2017-03-04 | Ipilimumab | 02 | N | 310016535 | IPILIMUMAB |
| 310002894 | 310006477 | 1.81 | 59.7 | Palliative (P) | 2017-07-06 | 2017-07-16 | DOXORUBICIN | N | N | 310016538 | DOXORUBICIN |
| 310002895 | 310006477 | 1.7 | 8.6 | Palliative (P) | 2016-01-15 | 2016-01-16 | Doxorubicin 75mg/m2 | N | N | 310016538 | DOXORUBICIN |
| 310002896 | 310010282 | null | null | Adjuvant (A) | 2017-08-24 | 2017-09-01 | Cisplatin | N | N | 310016545 | CISPLATIN |
| 310002897 | 310001239 | 0 | 64.9 | Curative (C) | 2015-06-14 | 2015-07-03 | Retinoblastoma JOE | N | N | 310016547 | CEV |
| 310002898 | 310001240 | 1.65 | 76.5 | Palliative (P) | 2017-10-29 | 2017-10-30 | Doxorubicin 75mg/m2 | N | N | 310016551 | DOXORUBICIN |